<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408551</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000515900</org_study_id>
    <secondary_id>CCCGHS-CHEMO-SIRT</secondary_id>
    <nct_id>NCT00408551</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver</brief_title>
  <official_title>A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goshen Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Internal radiation uses&#xD;
      radioactive material placed directly into or near a tumor to kill tumor cells. Giving&#xD;
      chemotherapy together with internal radiation may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving chemotherapy together with internal&#xD;
      radiation works in treating patients with colorectal cancer that has spread to the liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the tumor response, as measured by total tumor mass, carcinoembryonic antigen&#xD;
           (CEA) level, measurable tumor volume by CT scan, and metabolic response by positron&#xD;
           emission tomography (PET) scan, in patients with colorectal cancer metastatic to the&#xD;
           liver undergoing chemotherapy and selective internal radiation therapy (SIRT) comprising&#xD;
           yttrium Y 90 resin microspheres.&#xD;
&#xD;
        -  Evaluate the hepatic toxicity of this regimen, as measured by ALT, alkaline phosphatase,&#xD;
           and bilirubin levels, in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the therapeutic efficacy of this regimen, using time to in-liver disease&#xD;
           progression as an end point, in these patients.&#xD;
&#xD;
        -  Evaluate the therapeutic efficacy of this regimen, using down-staging to resectability&#xD;
           as an end point, in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive 1 of the following chemotherapy regimens:&#xD;
&#xD;
        -  FOLFOX6: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2&#xD;
           hours on day 1. Patients also receive fluorouracil IV continously over 46 hours&#xD;
           beginning on day 1.&#xD;
&#xD;
        -  FOLFIRI: Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium&#xD;
           IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46&#xD;
           hours beginning on day 1.&#xD;
&#xD;
        -  FUDR: Patients receive floxuridine IV continuously on days 1-14. In all chemotherapy&#xD;
           regimens, treatment repeats every 2 weeks for up to 8 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Patients also undergo selective internal radiation therapy (SIRT) comprising yttrium Y 90&#xD;
      resin microspheres on day 2 of chemotherapy course 1 (for patients receiving FOLFOX6 or&#xD;
      FOLFIRI chemotherapy regimens) or on day 1, 2, 3, 4, or 5 of course 1 (for patients receiving&#xD;
      FUDR chemotherapy regimen). SIRT may repeat in week 10 or 12.&#xD;
&#xD;
      In week 18, patients may undergo surgery if down-staging has occurred or they may receive&#xD;
      more chemotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response as measured by carcinoembryonic antigen (CEA) level, RECIST criteria, and positron emission tomography (PET) scan</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic efficacy based on time from selective internal radiation therapy (SIRT) to in-liver disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FUDR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive floxuridine IV continuously on days 1-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>floxuridine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FUDR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_label>FOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_label>FOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal cancer* meeting 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Metachronous metastasis after resection of Dukes A-C (i.e., stage I-III) primary&#xD;
                  colon cancer with or without adjuvant chemotherapy&#xD;
&#xD;
               -  Metachronous metastasis after resection of primary rectal cancer with neoadjuvant&#xD;
                  or adjuvant chemotherapy&#xD;
&#xD;
               -  Synchronous metastatic liver disease with symptomatic or asymptomatic primary&#xD;
                  colorectal cancer NOTE: *If the patient has a second malignancy with liver&#xD;
                  metastasis potential, histologic or cytologic confirmation of the liver lesions&#xD;
                  may be performed as clinically indicated&#xD;
&#xD;
          -  Liver-only or liver-predominant disease with any of the following:&#xD;
&#xD;
               -  Unresected primary disease&#xD;
&#xD;
               -  Limited bone or lung disease&#xD;
&#xD;
               -  Potentially resectable nodal disease&#xD;
&#xD;
               -  Anastomotic disease&#xD;
&#xD;
          -  No active CNS metastasis or diffuse peritoneal metastasis&#xD;
&#xD;
          -  No hepatic metastases from a second malignancy&#xD;
&#xD;
          -  No predominant extrahepatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  WBC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2 mg/dL (without extrahepatic biliary obstruction)&#xD;
&#xD;
          -  Albumin &gt; 2 g/dL&#xD;
&#xD;
          -  INR &lt; 1.5 (without anticoagulation)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior external-beam radiotherapy to the liver&#xD;
&#xD;
          -  Concurrent targeted therapy agents (e.g., bevacizumab or cetuximab) allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth L. Pennington, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Goshen Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Cancer Care at Goshen General Hospital</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Center for Cancer Care at Goshen Gene</last_name>
      <phone>574-535-2858</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2006</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <name_title>Kenneth Lee Pennington</name_title>
    <organization>Center for Cancer Care at Goshen General Hospital</organization>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

